Q3 Preview: A Stabilizing Quarter For J&J In China?
This article was originally published in PharmAsia News
Executive Summary
Since J&J reported in July a slowdown for its sales for China, the Chinese economy has deteriorated further. Can several new initiatives help the largest U.S. healthcare company to recover in this critical market?
You may also be interested in...
David Now Goliath? Made In China PD-1s Sought After By Multinationals
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: